Date: 2015-04-27
Type of information: Licensing agreement
Compound: next-generation AAV vectors
Company: 4D Molecular Therapeutics (USA - CA) Roche (Switzerland)
Therapeutic area: undisclosed
Type agreement: licensing collaboration
Action mechanism: gene therapy.
Disease: undisclosed indications with high unmet medical need
Details: * On April 27, 2015, 4D Molecular Therapeutics, a leader in next-generation gene therapy vector discovery and product development, announced a collaboration and license agreement with Roche to discover and develop optimized next-generation AAV vectors for indications with high unmet medical need. 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel gene delivery vectors for use in gene therapy products. This partnership was facilitated by QB3, a multi-campus University of California (including UC Berkeley & UC San Francisco) research institute and biotech accelerator, which seeks to catalyze relationships between large companies and startups at QB3’s incubators. 4D Molecular Therapeutics is based in the QB3@953 and JLABS (Johnson&Johnson Innovation) laboratories in the Mission Bay area of San Francisco.
Financial terms: Financial details were not disclosed.
Latest news:
